A model for ligand binding at the muscarinic cholinergic receptor von Moreland, D.W.

Volltext

Effect of mutating aspart ate 103 to glutamate or asparagine in the Hm2 subtype on binding of agonists and antagonists of varied pKa and subtype selectivity von Spencer, C.J., Schwarz, R.D., Moreland, D.W., Thomas, A.J., Tecle, H.

Volltext

Effect of mutating aspart ate 103 to glutamate or asparagine in the Hm2 subtype on binding of agonists and antagonists of varied pK a and subtype selectivity von Spencer, C.J., Schwarz, R.D., Moreland, D.W., Thomas, A.J., Tecle, H.

Volltext

Identification and characterization of m4 selective muscarinic antagonists von Augelli-Szafran, C.E., Moreland, D.W., Nelson, C.B., Penvose-Yi, J.R., Schwarz, R.D., Jaen, J.C.

Volltext

Synthesis and Sar of bulky 1-azabicyclo[2.2.1]-3-one oximes as muscarinic receptor subtype selective agonists von Tecle, H., Lauffer, D.J., Mirzadegan, T., Moos, W.H., Moreland, D.W., Pavia, M.R., Schwarz, R.D., Davis, R.E.

Volltext

Identification and characterization of m1 selective muscarinic antagonists von Augelli-Szafran, C.E., Blankley, C.J., Jaen, J.C., Moreland, D.W., Nelson, C.B., Penvose, J.R., Schwarz, R.D., Thomas, A.J.

Volltext

Aryleneyne 1-azabicyclo[2.2.1]heptan-3-one oximes: Potent muscarinic agonists von Tecle, H., Lauffer, D.J., Davis, R.E., Mirzadegan, T., Moreland, D.W., Schwarz, R.D., Thomas, A.J., Raby, C., Jaen, J.C.

Volltext

CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology von Tecle, H, Schwarz, R.D, Barrett, S.D, Callahan, M.J, Caprathe, B.W, Davis, R.E, Doyle, P, Emmerling, M, Lauffer, D.J, Mirzadegan, T, Moreland, D.W, Lipiniski, W, Nelson, C, Raby, C, Spencer, C, Spiegel, K, Thomas, A.J, Jaen, J.C

Volltext

(±)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-methyl-5-aryl-2-penten-4-ynyl) oximes: Potent muscarinic agonists von Tecle, H., Lauffer, D.J., Davis, R.E., Mirzadegan, T., Moreland, D.W., Schwan, R.D., Thomas, A.J., Raby, C., Eubanks, D., Brann, M.R., Jaen, J.C.

Volltext

A rationale for the design and synthesis of m1 selective muscarinic agonists von Tecle, H., Mirzadegan, T., Moos, W.H., Moreland, D.W., Pavia, M.R., Schwarz, R.D., Davis, R.E.

Volltext

Z-(±)-1-azabicyclo[2.2.1]heptan-3-one, O-(3-aryl-2-propynyl) oximes as potential m1-subtype selective muscarinic agonists von Tecle, H., Jaen, J.C., Augelli-Szafran, C., Barrett, S.D., Caprathe, B.W., Lauffer, D.J., Mirzadegan, T., Moos, W.H., Moreland, D.W., Pavia, M.R., Schwarz, R.D., Thomas, A.J., Davis, R.E.

Volltext

Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms von Larkin, James R, Anthony, Susan, Johanssen, Vanessa A, Yeo, Tianrong, Sealey, Megan, Yates, Abi G, Smith, Claire Friedemann, Claridge, Timothy D W, Nicholson, Brian D, Moreland, Julie-Ann, Gleeson, Fergus, Sibson, Nicola R, Anthony, Daniel C, Probert, Fay

Volltext

Early Childhood Educators’ Adverse Childhood Experiences (ACEs) Link with Psychological and Economic Wellbeing von Sullivan, Alexandra D. W., Rancher, Caitlin, Moreland, Angela

Volltext